Complications
| All patients (n=1134) | MACCE (n=124) | Bleeding complications (n=108) | |
| Cardiovascular complications, n (%) | |||
| Stroke | – | 1 (0.8) | – |
| Pulmonary oedema | 20 (16.1) | ||
| Cardiogenic shock | 14 (11.3) | ||
| Significant arrhythmia | 16 (12.9) | ||
| Acute limb ischaemia | 2 (1.6) | ||
| Myocardial infarction | 71 (57.2) | ||
| ST | 17 (13.7) | ||
| Definite | 10 | ||
| Probable | 3 | ||
| Possible | 4 | ||
| Time to ST (days) | 2 (0–8) | ||
| Death (associated with ST) | 5 (29.4) | ||
| Bleeding complications, n (%) | |||
| Site | |||
| Surgical | – | – | 92 (85.2) |
| Gastrointestinal | 7 | ||
| Retroperitoneal | 1 | ||
| Other | 3 | ||
| Repeat surgery to treat bleeding | 20 (18.5) | ||
| Transfusion, n (%) | 143 (12.6) | 33 (26.6) | 84 (77.8) |
| Erythrocytes | 33 (26.6) | 84 (100) | |
| Plasma | 5 (4) | 9 (8.3) | |
| Platelets | 5 (4) | 9 (8.3) | |
| Major bleeding complications | 92 (85.2) | ||
| Timing of complication | |||
| After procedure (%) | – | 100 | 84 |
| Time after surgery (days) | 3.3±3.9 | 5.3±5.3 | |
| Death rate, n (%) (95% CI) | 25 (2.2) (1.4 to 3.2) | 18 (14.5) (8.8 to 22.0) | 13 (12) (6.6 to 19.7) |
MACCE, major adverse cardiac and cerebrovascular events; ST, stent thrombosis.